Recent Updates
Recently added Catalysts

Compensated Chronic Hepatitis B: one US-listed biotech with a clinical-stage programme

Infectious Disease & VaccinesUncontestedData as of 2026-09-04

Competitors1in the clinic
Median market cap$1.9Buniverse median $1.20B
Allocated capital$484M$1.9B competing
Phase 3 or filed01 mid, 0 early
Pure plays0this indication only
Capital rank205/299crowding rank 210

Compensated Chronic Hepatitis B is uncontested. Vir Biotechnology (VIR) is the only US-listed developer in the $100M to $20B band running a clinical programme here, with PEG-IFNα in phase 2.

There is no public comparable to price it against. VIR spreads its $1.9B market cap across 4 indications, so $484M of it is allocated here.

Nothing here has reached Phase 3: 1 programme in mid stage and 0 in early stage, so the field is still several years from a first approval.

$484M of allocated capital sits in Compensated Chronic Hepatitis B, ranking it 205th of 299 indications by the money committed to it.

Companies developing drugs for Compensated Chronic Hepatitis B 1

TickerCompanyLead assetPhaseTrialsMarket capPure playIndicationsNext catalyst
VIRVir BiotechnologyPEG-IFNαPhase 25$1.9BNo4 31 Mar 2027

Sorted by phase, then by market capitalisation. Ticker links open the company profile.

Why Compensated Chronic Hepatitis B counts as uncontested

Uncontested. One US-listed developer in the size band is running a clinical programme here, so there is no public comparable to price it against.

The map splits indications on two folds: six or more competitors counts as crowded, and a median company above $1.20B counts as richly priced. Compensated Chronic Hepatitis B has one competitor and a median of $1.9B.

Infectious Disease & Vaccines

Infectious Disease & Vaccines holds $16.5B of the map's capital, 2.5% of the total, spread across 13 indications and 10 companies. 0 of those indications have more than one company competing.

See every Infectious Disease & Vaccines indication on the map

Related indications in Infectious Disease & Vaccines

Chronic Hepatitis B1 company · $484M · median $1.9BUncontestedHepatitis C1 company · $467M · median $467MUncontestedRSV Infection1 company · $408M · median $408MUncontestedSepsis1 company · $723M · median $8.7BUncontestedSmallpox1 company · $232M · median $232MUncontestedMycobacterium Abscessus Infection1 company · $771M · median $1.5BUncontestedIntra-Abdominal Infections1 company · $771M · median $1.5BUncontestedHepatitis B1 company · $13M · median $203MUncontested

Compensated Chronic Hepatitis B pipeline questions

Which biotech companies are developing drugs for Compensated Chronic Hepatitis B?

Vir Biotechnology (VIR, PEG-IFNα, Phase 2). Those are the 1 US-listed developer in the $100M to $20B market cap band with a clinical-stage programme in Compensated Chronic Hepatitis B.

How advanced is the Compensated Chronic Hepatitis B pipeline?

Of the 1 clinical-stage programme in Compensated Chronic Hepatitis B, 0 are in Phase 3 or filed, 1 is in mid-stage development and 0 are in early-stage development.

Is anyone else developing a drug for Compensated Chronic Hepatitis B?

No. VIR is the only US-listed company in the $100M to $20B market cap band with a clinical-stage programme in Compensated Chronic Hepatitis B, which is why the indication is classified as uncontested.

When is the next Compensated Chronic Hepatitis B catalyst?

The next dated catalyst in Compensated Chronic Hepatitis B is VIR on 31 Mar 2027. 1 dated event across the field fall in the next 12 months.

How this page is built

  • Universe is US-listed drug developers with a $100M to $20B market capitalisation, identified by SEC SIC code 2833, 2834 or 2836 or by a pharmaceutical or biotechnology industry classification, less a reviewed exclusion list of contract research organisations, device and diagnostics makers and diversified generics manufacturers.
  • An asset attributed to three or more different companies is treated as shared standard of care rather than any one company’s programme and excluded. Pembrolizumab alone appears under 21 tickers in raw trial data.
  • A programme counts only where at least one industry-sponsored trial supports it, so investigator-initiated academic studies of third-party drugs are excluded.

Allocated capital divides each company’s market capitalisation evenly across the indications it is running clinical programmes in, so every dollar of the universe is counted exactly once. Total market capitalisation competing counts a company in each of its indications and therefore sums to more than the universe.

Third-party market size estimates are not used anywhere on this page. Approved incumbents are excluded from competitor counts, and companies above $20B are outside the universe by construction.

Back to the disease map